



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1.	of	2
-------	----	----	---

**Complete if Known**

Application Number	10/030,452
Filing Date	January 10, 2002
First Named Inventor	Masayuki YABUTA et al.
Group Art Unit	1646
Examiner Name	To Be Assigned <i>Asp</i>
Attorney Docket Number	58777.000008

**U.S. PATENT DOCUMENTS**

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

**Examiner  
Signature**

Agnes B. Rooke

Date  
Considered

1/6/06

Signature Hopner B. [illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>3</sup> Enter Office that issued the document, by the two-letter code

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

to place a check mark here if English language Translation is attached.

**Business Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box



Date 10/19/2005

PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031.  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

## Complete if Known

Application Number	10/030,452
Filing Date	January 10, 2002
First Named Inventor	Masayuki YABUTA et al
Group Art Unit	1646
Examiner Name	To Be Assigned Agnes Rodas
Attorney Docket Number	58777.000008

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AR	P1	TSAL, Larry B. et al., "Control of Misincorporation of De Novo Synthesized Norleucine into Recombinant Interleukin-2 in <i>E. Coli</i> ," <i>Biochemical and Biophysical Communications</i> , 156(2):733-739 (1988).	
	P2	BOGOSIAN, George, "Biosynthesis and Incorporation into Protein of Norleucine by <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 264(1):531-539 (1989).	
	P3	APOSTOL, Izydor, et al., "Incorporation of Norvaline at Leucine Positions in Recombinant Human Hemoglobin Expressed in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 272(46):28980-28988 (1997).	
	P4	KANGAWA, Kenji, et al., "Purification and Complete Amino Acid Sequence of $\alpha$ -Human Atrial Natriuretic Polypeptide ( $\alpha$ -hANP)," <i>Biochemical and Biophysical Research Communications</i> , 118(1):131-139 (1984).	
	P5	MASAKI, Takeharu: et al., "Studies on a New Proteolytic Enzyme from <i>Achromobacter Lyticus</i> M4971 II. Specificity and Inhibition Studies of <i>Achromobacter</i> Protease 1," <i>Biochimica et Biophysica Acta</i> , 660:51-55 (1981).	
	P6	NEIDHARDT, Frederick C., et al., "Chemical Composition of <i>Escherichia coli</i> ," <i>Escherichia coli and Salmonella Cellular and Molecular Biology</i> , Vol. I, pp. 13-16, ASM Press, Washington, DC (1996).	
	P7	TWIGG, Andrea J., et al., "Trans-Complementable Copy-Number Mutants of Plasmid ColE1," <i>Nature</i> , 283:218-219 (1980).	
	P8	KREDICH, Nicholas M., "Biosynthesis of Cysteine," <i>Escherichia coli and Salmonella Cellular and Molecular Biology</i> , Vol. I, pp.514-527, ASM Press, Washington, DC (1996).	
	P9	VOET, Donald et al., <i>Biochemistry</i> , Vol. 2, Second Edition, Tokyo Kagaku Dojin, pp. 869-870 (1988).	

Examiner Signature

Agnes B. Rodas

Date Considered

1/6/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number: <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.